Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.58 |
| ▸ | BRAF | P15056 | 6/20 | 0.58 |
| ▸ | RAF1 | P04049 | 5/20 | 0.58 |
| ▸ | TEK | Q02763 | 5/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.43 |
| ▸ | CDK8 | P49336 | 3/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | CIT | O14578 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MUSK | O15146 | 1/20 | 0.40 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4541465 | 0.87 | KDR (0.52) | KDRBRAFRAF1METFGFR1 | |
| SCHEMBL4360543 | 0.87 | KDR (0.57) | KDRBRAFRAF1MEN1CSNK1A1 | |
| SCHEMBL4360523 | 0.85 | KDR (0.56) | KDRBRAFRAF1TEKMAPK14 | |
| SCHEMBL5790777 | 0.84 | KDR (0.62) | KDRBRAFRAF1MEN1CSNK1A1 | |
| SCHEMBL4372559 | 0.81 | KDR (0.85) | KDRBRAFRAF1TEKMAPK14 | |
| SCHEMBL17522957 | 0.81 | RAF1 (0.75) | KDRBRAFRAF1TEKMAPK14 | |
| SCHEMBL13861959 | 0.81 | KDR (0.61) | KDRBRAFRAF1FGFR1FLT1 | |
| SCHEMBL4363514 | 0.80 | RAF1 (0.88) | KDRBRAFRAF1TEKMAPK14 | |
| SCHEMBL4366061 | 0.79 | KDR (0.88) | KDRTEKCDK8METCDK2 | |
| SCHEMBL14601467 | 0.77 | RAF1 (0.66) | KDRBRAFRAF1TEKTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885BRAF 612/4885RAF1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.